This is the rationale for the development of novel immunotherapies that increase the numbers of effector CD8+ T cells and target immune checkpoints responsible for normalizing, re-establishing or augmenting effector CD8+ T cell function against tumor cell [23]. The gene discussed is CD8A; the disease is neoplasm.